IGM Biosciences to Present at Two Upcoming Investor Conferences
07 Novembre 2023 - 1:00PM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company focused on creating and developing engineered
IgM antibodies, today announced that Fred Schwarzer, Chief
Executive Officer, will present at two upcoming investor
conferences:
- Stifel Healthcare Conference on
Tuesday, November 14 at 2:25 p.m. EST in New York
- Jefferies London Healthcare
Conference on Thursday, November 16 at 9:00 a.m. GMT/ 4:00 a.m. EST
in London
A live webcast of the events will be available
on the “Events and Presentations” page in the “Investors” section
of the Company’s website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcasts will be archived on the Company’s website
for 90 days following the presentations.
About IGM Biosciences, Inc.IGM
Biosciences is a clinical-stage biotechnology company committed to
developing and delivering a new class of medicines to treat
patients with cancer, autoimmune and inflammatory diseases and
infectious diseases. IGM’s pipeline of clinical and preclinical
assets is based on the IgM antibody, which has 10 binding sites
compared to conventional IgG antibodies with only 2 binding sites.
IGM also has an exclusive worldwide collaboration agreement with
Sanofi to create, develop, manufacture, and commercialize IgM
antibody agonists against oncology and immunology and inflammation
targets. For more information, please visit www.igmbio.com.
Contact:Argot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
Grafico Azioni IGM Biosciences (NASDAQ:IGMS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni IGM Biosciences (NASDAQ:IGMS)
Storico
Da Giu 2023 a Giu 2024